Progressive Multiple Sclerosis
|
|
- Dortha Cobb
- 5 years ago
- Views:
Transcription
1 Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of Utah 8 th PVA Healthcare Summit Dallas, Texas 28-August-2018
2 Disclosures Presenter has no financial or non-financial interest to disclose. PESG staff, PVA staff, and planning/review committee members have no financial or non-financial interest to disclose. This continuing education activity is managed and accredited by Professional Education Services Group in cooperation with Paralyzed Veterans of America. PESG, PVA, and all accrediting organization do not support or endorse any product or service mentioned in this activity.
3 Objectives At the conclusion of this activity, the participant will be able to: Describe the clinical and radiological characteristics of progressive versus relapsing MS. Describe the impact of relapses and DMT on the course of progressive MS. Discuss emerging treatments for progressive MS.
4 Progressive MS What is progressive MS?
5 Progressive MS: definitions Progression process of moving gradually towards a more advanced state Progressive disease disease that is spreading or whose course is worsening Stedman's Medical Dictionary
6
7 Progressive MS: definitions Schumacher 1965 slow or step-wise progression of signs and symptoms, over a period of at least 6 months Poser 1983 steady progression has taken place for at least 6 months, and evidence for [other CNS] involvement should not have been present at the time paraparesis first appeared McDonald 2001 insidious neurological progression suggestive of MS dissemination in space (MRI +/- VEP) continued progression for 1 year positive CSF Schumacher et al, Ann NY Acad Sci 1965 Poser et al, Ann Neurol 1983 McDonald et al, Ann Neurol 2001
8 Progressive MS: definitions McDonald 2005 insidious neurological progression suggestive of MS 1 year of disease progression two of the following + brain MRI, + spinal cord MRI, + CSF McDonald 2010 insidious neurological progression suggestive of MS same as 2005, with less strict MRI criteria McDonald year of disability progression independent of clinical relapse two of the following (same as 2010) Polman et al, Ann Neurol 2005 Polman et al, Ann Neurol 2011 Thompson et al, Lancet Neurol 2018
9 Progressive MS: definitions Progressive disease course insidious accumulation of neurologic deficits independent of relapses and MRI activity Progression of disability insidious accumulation independent of relapses stepwise accumulation from relapses Weinshenker et al, Brain 1989; Trojano et al, JNNP 1995 Kantarci et al, Neurology 1998; Confavreux et al, Brain 2006 Tutuncu et al, MSJ 2012
10 Progressive MS: disease course Two clinical patterns of MS symptoms MS subtypes based on presence/timing Disability Relapsing Progressive RR SP PP PR Lublin FD Reingold SC, Neurology 1996
11 Progressive MS: disease course Is primary progressive MS a distinct disease? Miller DH Leary SM, Lancet Neurol 2007
12 Progressive MS: disease course Multiple sclerosis PPMS vs RRMS/SPMS Tutuncu et al. MSJ 2012 Confavreux et al. NEJM 2000
13 Progressive MS: disease course Two clinical patterns of MS symptoms MS subtypes based on presence/timing Disability Relapsing Progressive RR SP PP PR Lublin FD Reingold SC, Neurology 1996
14 Progressive MS: disease course Two clinical patterns of MS symptoms MS subtypes based on presence/timing CIS RIS Marcus et al, Neurohospitalist 2013 Okuda et al, PLoS One 2014
15 Progressive MS: disease course Kantarci et al, Ann Neurol 2016
16 Progressive MS: disease course Two clinical patterns of MS symptoms MS subtypes based on presence/timing CIS RRMS CIS SPMS RIS RRMS RIS PPMS Marcus et al, Neurohospitalist 2013 Okuda et al, PLoS One 2014
17 Progressive MS: disease course Multiple sclerosis PPMS vs RRMS/SPMS Tutuncu et al. MSJ 2012 Confavreux et al. NEJM 2000
18 Progressive MS: disease course Multiple sclerosis PPMS vs RRMS/SPMS Tutuncu et al. MSJ 2012 Kremenchutzky et al. Brain 2006
19 Progressive MS: definitions Progressive disease course insidious accumulation of neurologic deficits independent of relapses and MRI activity strongest determinant of disability progression Progression of disability insidious accumulation independent of relapses stepwise accumulation from relapses small % of patients reach EDSS 6 before progression Weinshenker et al, Brain 1989; Trojano et al, JNNP 1995 Kantarci et al, Neurology 1998; Confavreux et al, Brain 2006 Tutuncu et al, MSJ 2012
20 Progressive MS: impact of relapses Progressive MS onset to EDSS6 (yrs) HR: 2.20 ( ) HR: 1.48 ( ) pre-progression relapses post-progression relapses Paz Soldan et al, Neurology 2015
21 Progressive MS: impact of relapses Time to EDSS 6 after progressive MS onset Pre-progression relapses SPMS SAPMS PPMS = 50% in 4 years = 50% in 7 years = 50% in 10 years Paz Soldan et al, Neurology 2015
22 Progressive MS: impact of relapses Relapsing onset = faster disability accrual Cottrell 1999, Kremenchutzky 1999 Confavreux 2006 Debouverie 2008 (trend) Tremlett 2009 Disability accrual not influenced by initial disease course Confavreux 2000 Trojano 2002 Kremenchutzky 2006, Scalfari 2011 Leray 2010 Methodological differences progression onset, EDSS milestones
23 Progressive MS: impact of relapses Time to EDSS 6 after progressive MS onset Pre-progression relapses SPMS SAPMS PPMS = 50% in 4 years = 50% in 7 years = 50% in 10 years Post-progression relapses 2 yrs. shorter with ongoing relapses Paz Soldan et al, Neurology 2015
24 Progressive MS: impact of relapses Presence of ongoing relapses after progressive MS onset SPMS = 29.5% SAPMS = 10.7% PPMS = 3.1% Timing of ongoing relapses after progressive MS onset 91.6% within 5 years 95.2% before age 55 Paz Soldan et al, Neurology 2015
25 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 Hartung et al, Lancet 2002
26 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 Hartung et al, Lancet 2002
27 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 ocrelizumab for PPMS March 2017
28 Progressive MS: therapy FDA approved DMTs ocrelizumab for PPMS March 2017 Montalban et al, NEJM 2017
29 Progressive MS: therapy FDA approved DMTs ocrelizumab for PPMS positive rituximab for PPMS negative Hawker et al, Ann Neurol 2009
30 Progressive MS: therapy FDA approved DMTs ocrelizumab for PPMS positive mean age 44.6 years disease activity at baseline gadolinium + lesions 26.5% rituximab for PPMS negative mean age 49.9 years disease activity at baseline gadolinium + lesions 24.5% Hawker et al, Ann Neurol 2009
31 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 ocrelizumab for PPMS March 2017 rituximab for PPMS negative Emerging DMTs siponimod for SPMS positive
32 Progressive MS: therapy Emerging DMTs siponimod for SPMS Randomized 2:1 to siponimod (1099) or placebo (546) 449 CDP events captured risk of 3-month CDP reduced 21% risk of 6-month CDP reduced 26% T25FW not significant Kappos et al, Lancet 2018
33 Progressive MS: therapy Emerging DMTs siponimod for SPMS positive fingolimod for PPMS negative Kappos et al, Lancet 2018 Lublin et al, Lancet 2016
34 Progressive MS: therapy Emerging DMTs siponimod for SPMS positive mean age 48 years disease activity in year prior gadolinium + lesions 21% clinical relapses 22% fingolimod for PPMS negative mean age 48.5 years disease activity in year prior gadolinium + lesions 13% clinical relapses ~8% Kappos et al, Lancet 2018 Lublin et al, Lancet 2016
35 Progressive MS: therapy Emerging DMTs siponimod for SPMS Randomized 2:1 to siponimod (1099) or placebo (546) 449 CDP events captured risk of 3-month CDP reduced 21% risk of 6-month CDP reduced 26% T25FW not significant Kappos et al, Lancet 2018
36 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 ocrelizumab for PPMS March 2017 rituximab for PPMS negative Emerging DMTs siponimod for SPMS positive fingolimod for PPMS negative
37 Progressive MS: therapy Pathologic mechanisms of progressive MS?
38 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 ocrelizumab for PPMS March 2017 rituximab for PPMS negative Emerging DMTs siponimod for SPMS positive fingolimod for PPMS negative high-dose biotin
39 Progressive MS: therapy Emerging DMTs high-dose biotin Tourbah et al, Mult Scler 2016
40 Progressive MS: therapy Emerging DMTs high-dose biotin Tourbah et al, Mult Scler 2016
41 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 ocrelizumab for PPMS March 2017 rituximab for PPMS negative Emerging DMTs siponimod for SPMS positive fingolimod for PPMS negative high-dose biotin positive lipoic acid
42 Progressive MS: therapy Emerging DMTs lipoic acid Spain et al, Neurology 2017
43 Progressive MS: therapy Emerging DMTs lipoic acid Spain et al, Neurology 2017
44 Progressive MS: therapy FDA approved DMTs mitoxantrone for SPMS October 2000 ocrelizumab for PPMS March 2017 rituximab for PPMS negative Emerging DMTs siponimod for SPMS positive fingolimod for PPMS negative high-dose biotin positive lipoic acid positive
45 Progressive MS: disease course Lublin et al, Neurology 2014
46 Progressive MS: disease course Lublin et al, Neurology 2014
47 Progressive MS: definitions Active clinical relapses and/or MRI activity Progressive insidious accumulation of neurologic deficits independent of relapses and/or MRI activity Lublin et al, Neurology 2014
48 CE/CME Credit If you would like to receive continuing education credit for this activity, please visit:
49
1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationTop 10 Research Findings of 2016
Top 10 Research Findings of 2016 NMSS Regional Summit 2017 June 10, 2017 Rebecca Spain, MD, MSPH VA Portland Health Care System Oregon Health & Science University Disclosures Research support: NMSS Department
More informationMEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationEmerging Therapies for Progressive Multiple Sclerosis
Emerging Therapies for Progressive Multiple Sclerosis A number of agents with putative neuroprotective effects have shown promise in recent clinical trials. By Matthew Tremblay, MD, PhD Introduction Approximately
More informationNEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS
NEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS Jeffrey A. Cohen, MD Director, Experimental Therapeutics Mellen MS Center Neurological Institute Cleveland Clinic 2018 Regional MS Summit 30 June 2018 Disclosures
More information2013 MS Phenotype Descriptions: Relapsing MS 1
2013 MS Phenotype Descriptions: Relapsing MS 1 Disease-Modifying Therapies? which can be found in its entirety at. Clinically isolated syndrome (CIS) Not Active a Active a,b Relapsing-remitting disease
More informationTh1/Th17 Cytokine Dysregulation during Different Stages of Multiple Sclerosis
Th1/Th17 Cytokine Dysregulation during Different Stages of Multiple Sclerosis Benjamin M. Segal, M.D. Holtom-Garrett Professor of Neurology Director, Multiple Sclerosis Program University of Michigan Disclosures
More informationInnovazione e personalizzazione nella terapia della SM. Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila
Innovazione e personalizzazione nella terapia della SM Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila Which are the objectives of MS treatment? «Historically»
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationNeuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS
Neuroimaging and Other Biomarkers MRI for Diagnosis, Prognosis and Treatment Decisions in MS Eric Klawiter, MD MSc Massachusetts General Hospital May 30, 2014 Disclosures and Funding Disclosures: Consulting
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationEpidemiology, Diagnosis, Natural History & Clinical Course
Epidemiology, Diagnosis, Natural History & Clinical Course Multiple Sclerosis Immune-mediated, chronic, inflammatory disease precipitated by unknown environmental factors in genetically susceptible individuals
More informationSiponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value
Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Effectiveness and Value Background FINAL Background and Scope November 29, 2018 Multiple sclerosis (MS) is a chronic, immune-mediated
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker, II, MD University of Alabama at Birmingham June 2, 2016 DISCLOSURES Research Support: Biogen Idec; Department of
More informationUpdate on DMTs in Multiple Sclerosis
Update on DMTs in Multiple Sclerosis John R. Corboy, MD Professor, Neurology 3/4/2017 Disclosures Honoraria Board Member Research Editorial Prime CME NMSS Med Day; Novartis; Biogen; PCORI; NMSS Editor,
More informationProgram Highlights. A multidisciplinary AAN working group identified areas for improvement in the diagnosis and management of patients with MS
CasePerspectives: Illuminating Dark Pathways in Complex MS Cases Program Highlights Stephen Krieger, MD Associate Professor of Neurology Corinne Goldsmith Dickinson Center for MS Director, Neurology Residency
More informationDiagnosis and Monitoring of Patients With Multiple Sclerosis
Diagnosis and Monitoring of Patients With Multiple Sclerosis From the 2017 guidelines to newest modalities. By Edward Fox, MD, PhD; Esther Melamed, MD, PhD; and Elliot Frohman, MD, PhD Multiple sclerosis
More informationThe Current Clinical Arena of Progressive Multiple Sclerosis
The Current Clinical Arena of Progressive Multiple Sclerosis Carrie M. Hersh, DO Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio Abstract
More informationAnisha Keshavan. Roland Henry, PhD. Proportion of Patients (%) Rituximab 2000mg (n=66) Placebo (n=35)
Two Faces of Multiple Sclerosis February 8, 217 5 T H A N N U A L R E C E N T A D V A N C E S I N N E U R O L O G Y B CELL THERAPY FOR MULTIPLE SCLEROSIS: A NEW DAY? Inflammation Relapsing MS Anisha Keshavan
More informationMS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationMultiple Sclerosis Update
Multiple Sclerosis Update Amanda Stahnke, PharmD, BCACP University of Missouri-Kansas City School of Pharmacy Kansas City Veterans Affairs Honor Annex Kelsey Morris, PharmD University of Kansas Health-System
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org How
More informationInvestor Update. Downloads. Services PDF. Basel, 17 July 2017
Investor Update Basel, 17 July 2017 Roche s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and
More informationMS Prevalence and Patients' Characteristics in the District of Braga, Portugal
MS Prevalence and Patients' Characteristics in the District of Braga, Portugal Figueiredo, José[1]; Silva, Ângela [2]; Cerqueira, João J.[3,4]; Fonseca, Joaquim[5]; Pereira, Paulo A.[6]; 1 Neurology Dept.,
More informationNeurophysiology in diagnosis and monitoring of MS
ISTITUTO SCIENTIFICO UNIVERSITARIO SAN RAFFAELE MS Academia Amsterdam - October 18, 2011 Neurophysiology in diagnosis and monitoring of MS Letizia Leocani Dep.t of Neurology, Clin. Neurophysiol. and Neurorehabilitation
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationRoche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis
Media Release Basel, 28 September 2017 Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis OCREVUS is the first and only approved treatment
More informationGILENYA (fingolimod) oral capsule
GILENYA (fingolimod) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPage 1. Multiple Sclerosis. I have no conflicts of interest. Team Menstrual Cycles Waves to Wine for MS. Overview.
Multiple Sclerosis New Developments Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Team Menstrual
More informationMRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger
MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis E.W. Radue K. Bendfeldt Till Sprenger Medical Image Analysis Center University Hospital Basel www. miac.ch
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationThe natural history of secondary progressive multiple sclerosis
See Editorial Commentary, p 944 1 Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada 2 Department of Neurology, University Medical Centre Groningen, University
More informationDiagnostic Criteria, Clinical Courses, and Rating Scales in MS
Diagnostic Criteria, Clinical Courses, and Rating Scales in MS Introduction and Objectives Introduction This module will focus on diagnostic tools utilized in randomized clinical trials (RCTs) in MS. Diagnostic
More informationMedia Release. Basel 12 January 2018
Media Release Basel 12 January 2018 Roche s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved
More informationMedia Release. Basel, 10 November 2017
Media Release Basel, 10 November 2017 Roche s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS
More informationGILENYA (fingolimod) oral capsule
GILENYA (fingolimod) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationHoa Van Le, MD, PhD (Presenter) PAREXEL International ISPOR 22nd Annual International Meeting, Boston, MA. May 23, 2017
Lessons Learned in Identifying Relapsing- Remitting Multiple Sclerosis in US Integrated Delivery Network Health Care Claims and Electronic Health Record Data Hoa Van Le, MD, PhD (Presenter) PAREXEL International
More informationPATIENTS WITH MULTIPLE SCLEROSIS
3 PATIENTS WITH MULTIPLE SCLEROSIS PREFER EARLY DIAGNOSIS Abstract The new diagnostic criteria for multiple sclerosis (MS) allow for a definite diagnosis in earlier stages of disease. Yet, clinicians may
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker II, MD University of Alabama at Birmingham Birmingham VA Medical Center May 29, 2014 DISCLOSURES Salary/Research:
More informationTECFIDERA (dimethyl fumarate) oral capsule
TECFIDERA (dimethyl fumarate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMultiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J 2005;81: doi: /pgmj
302 REVIEW Multiple sclerosis: diagnosis and the management of acute relapses S M Leary, B Porter, A J Thompson... Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system
More informationOcrevus (ocrelizumab)
Ocrevus (ocrelizumab) Policy Number: 5.01.629 Last Review: 04/2018 Origination: 05/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ocrevus
More informationSecondary progressive MS: Diagnosis, symptomatic management, and outlook on potential therapies
Secondary progressive MS: Diagnosis, symptomatic management, and outlook on potential therapies Maria Fides Pacheco, M.D. Shirley O Leary, MS APRN-C, MSCN Olaf Stüve, M.D., Ph.D. Neurology Section VA North
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationSpinal cord MR imaging in Multiple Sclerosis
43ème CONGRÈS ANNUEL de la Société Française de NeuroRadiologie 30 mars au 1 er avril 2016 Novotel Paris Tour Eiffel Spinal cord MR imaging in Multiple Sclerosis Àlex Rovira Unitat de Neurorradiología.
More informationReal-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2018 ORIGINAL ARTICLE Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis Su-Hyun
More informationMultiple Sclerosis Surveillance Registry: Introduction and Overview
Multiple Sclerosis Surveillance Registry: Introduction and Overview PVA Summit-2016 Orlando, FL Mitchell Wallin, MD, MPH Interim Director, VA MSCoE-East Associate Professor of Neurology Georgetown University
More informationEfficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific
More informationEarliest MS: What Do We Know? RMMSC Education Summit May 12,2018. John R. Corboy, MD
Earliest MS: What Do We Know? RMMSC Education Summit May 12,2018 John R. Corboy, MD JRC has received grant support from PCORI, NMSS, Novartis, Biogen, and Med-Day. He receives compensation as the editor
More informationWhen should disease-modifying treatments be discontinued in patients with multiple sclerosis? An evidence-based review with expert recommendations.
When should disease-modifying treatments be discontinued in patients with multiple sclerosis? An evidence-based review with expert recommendations. Learning objective To understand the factors relevant
More informationNovartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis real-world data at AAN confirms
More informationAUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMultiple Sclerosis Society of New Zealand Inc.
MSTAC and Neurological Subcommittee C/o- Andrew Oliver PHARMAC PO Box 10-254 Wellington 6143 1 st June 2018 Dear Sirs, Background to Submission On Monday 28 th May members of Multiple Sclerosis New Zealand
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationORIGINAL CONTRIBUTION. Multiple Sclerosis That Is Progressive From the Time of Onset
ORIGINAL CONTRIBUTION Multiple Sclerosis That Is Progressive From the Time of Onset Clinical Characteristics and Progression of Disability P. B. Andersson, MBChB, DPhil; E. Waubant, MD; L. Gee, MPH; D.
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More informationDisclosures 6/26/2015
Salim Chahin, MD, MSCE Multiple Sclerosis division The University of Pennsylvania Disclosures I have no disclosure to report. This talk is based on published literature, survey of neurologists in Damascus,
More informationAssessing the Potential Implications of the Topographical Model of Multiple Sclerosis on Patient Practitioner Communication and Treatment Selection
CME Assessing the Potential Implications of the Topographical Model of Multiple Sclerosis on Patient Practitioner Communication and Treatment Selection Course Director Stephen Krieger, MD, FAAN Corinne
More informationRELAPSES ARE A MAJOR CAUSE OF IRREVERSIBLE
PAPER: APER: ACCUMULATION OF IRREVERSIBLE DISABILITY IN MULTIPLE SCLEROSIS LESSONS FROM NATURAL HISTORY STUDIES AND THERAPEUTIC TRIALS C Confavreux, Head of Neurology A and EDMUS Coordinating Centre, Hôpital
More informationMultiple Sclerosis Treatment
Special Supplement September 2014 Volume 16, Supplement 5 The Official Publication of the Consortium of Multiple Sclerosis Centers Optimizing Efficacy and Adherence to Multiple Sclerosis Treatment 2014
More informationMRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS
MRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS Maria A. Rocca Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute
More informationFingolimod for the treatment of Relapsing-Remitting Multiple Sclerosis
Novartis Neurosciences Therapeutic Area Fingolimod for the treatment of Relapsing-Remitting Multiple Sclerosis Renato Turrini Medical Head Franchise Neurosciences Milano, 22 giugno 2017 What is RWE? Real-world
More informationPrimary Progressive MS. Predicting Progression. Alan J Thompson Director, UCL Institute of Neurology Queen Square
Primary Progressive MS Predicting Progression Alan J Thompson Director, UCL Institute of Neurology Queen Square Disclosures Alan J Thompson UCL Institute of Neurology Queen Square London, UK In compliance
More informationTreating MS patients earlier in the disease progression may affect long-term outcomes 1-4
Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4 TIME DISEASE ONSET EARLY TREATMENT NATURAL COURSE OF MS LATER TREATMENT DISABILITY INCREASE The disease activity
More informationNegative prognostic impact of MRI spinal lesions in the early stages of relapsing remitting multiple sclerosis
Original Article Negative prognostic impact of MRI spinal lesions in the early stages of relapsing remitting multiple sclerosis E D Amico, F Patti, C Leone, S Lo Fermo and M Zappia Multiple Sclerosis Journal
More informationKaspar Rufibach Methods, Collaboration, and Outreach Group (MCO) Department of Biostatistics, Roche Basel
Construction of an Estimand in a Clinical Trial on Progressive Multiple Sclerosis Kaspar Rufibach Methods, Collaboration, and Outreach Group (MCO) Department of Biostatistics, Roche Basel Acknowledgments
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationMultiple sclerosis (MS) is an autoimmune disease of the
RESEARCH Determining Multiple Sclerosis Phenotype from Electronic Medical Records Richard E. Nelson, PhD; Jorie Butler, PhD; Joanne LaFleur, PharmD, MSPH; Kristin Knippenberg, MFA; Aaron W. C. Kamauu,
More informationThe invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationSupplementary Online Content
Supplementary Online Content Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol. Published online June
More informationMRI diagnostic criteria for multiple sclerosis: an update
MRI diagnostic criteria for multiple sclerosis: an update Poster No.: C-0285 Congress: ECR 2013 Type: Educational Exhibit Authors: L. Valls Masot, A. M. Quiles Granado, J. Puig Alcántara, L. RamióTorrentà,
More informationNEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS
NEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS Learning Objectives Daniel Harrison, MD University of Maryland School of Medicine Baltimore, MD Upon completion of this module, participants should be familiar with:
More informationMultiple Sclerosis (MS) is a
The role of interferon beta in multiple sclerosis management David J Rog MRCP, John P Mottershead MRCP, Greater Manchester Neurosciences Centre, Hope Hospital, Stott Lane, Manchester, M6 8HD SPL Multiple
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 July 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 July 2011 GILENYA 0.5 mg, hard capsules, perforated unit dose blister packs B/7 (CIP code: 417 785-3) GILENYA 0.5
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Gabelić T., Radmilović M., Posavec V., Škvorc A., Bošković M., Adamec I., Milivojević I., Barun B., Habek M. (2013) Differences in oligoclonal bands and visual evoked potentials
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 343 N OVEMBER 16, 2 NUMBER 2 RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS CHRISTIAN CONFAVREUX,
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationStarting Disease-modifying Therapy (DMT) Recommendations
AAN Summary of Practice Guideline for Clinicians Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis This is a summary of the American Academy of Neurology (AAN) publication,
More informationPrimary progressive multiple sclerosis: a 5-year clinical and MR study
DOI: 10.1093/brain/awg261 Advanced Access publication August 5, 2003 Brain (2003), 126, 2528±2536 Primary progressive multiple sclerosis: a 5-year clinical and MR study G. T. Ingle, 1 V. L. Stevenson,
More informationABSTRACT ORIGINAL RESEARCH. Ralf Gold. Gavin Giovannoni. J. Theodore Phillips. Robert J. Fox. Annie Zhang. Jing L. Marantz
Neurol Ther (2016) 5:45 57 DOI 10.1007/s40120-016-0042-8 ORIGINAL RESEARCH Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing Remitting Multiple Sclerosis:
More informationChange in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis
c An additional table is published online only at http:// jnnp.bmj.com/content/vol79/ issue10 1 Helen Durham Neuroinflammatory Centre, Department of Neurology, University Hospital of Wales, Heath Park,
More informationTherapeutic Decision Making in a New Drug Era in Multiple Sclerosis
5 Therapeutic Decision Making in a New Drug Era in Multiple Sclerosis B. Mark Keegan, MD, FRCP(C) 1 1 Department of Neurology, Mayo Clinic, Rochester, Minnesota Semin Neurol 2013;33:5 12. Address for correspondence
More informationBenefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints 1 Learning Objectives Review the benefit/risk strategies in selecting therapy for MS patients while assessing
More informationSupplementary Online Content
Supplementary Online Content Kappos L, Li DKB, Stüve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the
More informationInsights for Payers. RMS Treatment Considerations and Real-World Evidence Based on a Milliman Actuarial Analysis. RMS=relapsing multiple sclerosis.
Insights for Payers RMS Treatment Considerations and Real-World Evidence Based on a Milliman Actuarial Analysis RMS=relapsing multiple sclerosis. 2016 Biogen. All rights reserved. 10/16 FCH-US-1971 Agenda
More informationMRI in MS: the radiologist perspective
MS Preceptorship - Updating Knowledge in Multiple Sclerosis - June, 1-3 2010 Barcelona MRI in MS: the radiologist perspective Àlex Rovira Unidad de Resonancia Magnética Servicio de Radiología Hospital
More informationMultiple sclerosis (MS) is a chronic autoimmune
Multiple sclerosis in older people Multiple sclerosis (MS) is the most common chronic disabling disease of the central nervous system in young adults. The late-onset MS (LOMS) variety, with clinical onset
More informationMULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson
MULTIPLE SCLEROSIS IN 2015 Managing the complexity of multiple sclerosis Olga Ciccarelli and Alan Thompson The application of imaging biomarkers has provided new insights into the mechanisms of damage
More informationPATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day
Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 6 PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M
More informationProgression Rates and Sample Size Estimates for Primary Progressive Multiple Sclerosis Based on the CLIMB Study Population
Progression Rates and Sample Size Estimates for Primary Progressive Multiple Sclerosis Based on the CLIMB Study Population The Harvard community has made this article openly available. Please share how
More informationPediatric acute demyelinating encephalomyelitis in Denmark: a nationwide population-based study
Pediatric acute demyelinating encephalomyelitis in Denmark: a nationwide population-based study Magnus Spangsberg Boesen November, 2016 Supervisors: P. Born, P. Uldall, M. Blinkenberg, M. Magyari, F. Sellebjerg
More information